PL2844759T3 - Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens - Google Patents
Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigensInfo
- Publication number
- PL2844759T3 PL2844759T3 PL12823073T PL12823073T PL2844759T3 PL 2844759 T3 PL2844759 T3 PL 2844759T3 PL 12823073 T PL12823073 T PL 12823073T PL 12823073 T PL12823073 T PL 12823073T PL 2844759 T3 PL2844759 T3 PL 2844759T3
- Authority
- PL
- Poland
- Prior art keywords
- vaccination
- producing
- immune response
- response against
- humoral immune
- Prior art date
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 230000028996 humoral immune response Effects 0.000 title 1
- 230000001681 protective effect Effects 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011121069A DE102011121069A1 (en) | 2011-12-13 | 2011-12-13 | Vaccination by recombinant yeast by generating a protective humoral immune response against defined antigens |
| PCT/DE2012/001205 WO2013107436A1 (en) | 2011-12-13 | 2012-12-12 | Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens |
| EP12823073.7A EP2844759B1 (en) | 2011-12-13 | 2012-12-12 | Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2844759T3 true PL2844759T3 (en) | 2019-01-31 |
Family
ID=47681476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12823073T PL2844759T3 (en) | 2011-12-13 | 2012-12-12 | Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11065312B2 (en) |
| EP (1) | EP2844759B1 (en) |
| JP (1) | JP6313215B2 (en) |
| KR (1) | KR102027400B1 (en) |
| CN (1) | CN104428417B (en) |
| BR (1) | BR112014014390B1 (en) |
| CA (1) | CA2859231C (en) |
| DE (2) | DE102011121069A1 (en) |
| DK (1) | DK2844759T3 (en) |
| ES (1) | ES2690792T3 (en) |
| MX (1) | MX368484B (en) |
| PL (1) | PL2844759T3 (en) |
| RU (1) | RU2630620C2 (en) |
| WO (1) | WO2013107436A1 (en) |
| ZA (1) | ZA201405034B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102017012109A1 (en) * | 2017-12-27 | 2019-06-27 | Martin-Luther-Universität Halle-Wittenberg | Optimized host / vector system for the generation of protective mono- and multivalent subunit vaccines based on the yeast Kluyveromyces lactis |
| CN109467606A (en) * | 2018-11-15 | 2019-03-15 | 大连理工大学 | A kind of Escherichia coli enterotoxin STa-LTB-STb fusion protein and its encoding gene and application |
| JP7372647B2 (en) * | 2019-06-27 | 2023-11-01 | 国立研究開発法人農業・食品産業技術総合研究機構 | Yeast with improved α-linolenic acid production ability or its culture |
| CN110646614B (en) * | 2019-07-15 | 2023-05-23 | 新乡学院 | ELISA kit and test method for IBDV antibody and effective antibody titer determination method |
| CN114870006A (en) * | 2022-04-13 | 2022-08-09 | 河北农业大学 | ETEC vaccine and application thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU643216B2 (en) * | 1989-05-30 | 1993-11-11 | Commonwealth Scientific And Industrial Research Organisation | Production of IBDV VP2 in highly immunogenic form |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US6234977B1 (en) | 2000-01-28 | 2001-05-22 | Michael Christy | Variable-force monofilament sensory device and methods of using same |
| WO2002039951A2 (en) | 2000-11-15 | 2002-05-23 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| MXPA05010113A (en) * | 2003-03-24 | 2005-11-23 | Akzo Nobel Nv | Infectious bursal disease virus mutants and vaccines. |
| ES2242542B1 (en) | 2004-04-30 | 2006-12-16 | Consejo Superior De Investigaciones Cientificas | PROCEDURE FOR THE PRODUCTION IN LEAVES OF EMPTY VIRAL CAPSIDES COMPOSED BY PROTEINS DERIVED FROM PVP2 OF THE VIRUS CAUSING THE INFECTIOUS BURSITIS DISEASE (IBDV). |
| US20090317420A1 (en) * | 2004-07-29 | 2009-12-24 | Chiron Corporation | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
| JP2008516610A (en) | 2004-10-18 | 2008-05-22 | グローブイミューン，インコーポレイテッド | Treatment of chronic hepatitis C infection using yeast |
| CA2638815A1 (en) | 2006-02-02 | 2007-08-16 | Globeimmune, Inc. | Yeast-based vaccine for inducing an immune response |
| KR101001023B1 (en) * | 2007-06-12 | 2010-12-14 | 성균관대학교산학협력단 | Vaccines for the treatment or prevention of Pasteurella using the yeast surface expression system |
| DE102008057451A1 (en) * | 2008-11-14 | 2010-05-20 | Martin-Luther-Universität Halle-Wittenberg | Method for oral vaccination by means of recombinant yeasts |
| CN101638824B (en) | 2009-03-16 | 2012-08-08 | 浙江双友物流器械股份有限公司 | Wear resistant woven belt |
| WO2011032119A1 (en) | 2009-09-14 | 2011-03-17 | The Regents Of The University Of Colorado | Modulation of yeast-based immunotherapy products and responses |
-
2011
- 2011-12-13 DE DE102011121069A patent/DE102011121069A1/en not_active Ceased
-
2012
- 2012-12-12 BR BR112014014390-0A patent/BR112014014390B1/en active IP Right Grant
- 2012-12-12 ES ES12823073.7T patent/ES2690792T3/en active Active
- 2012-12-12 CA CA2859231A patent/CA2859231C/en active Active
- 2012-12-12 EP EP12823073.7A patent/EP2844759B1/en active Active
- 2012-12-12 PL PL12823073T patent/PL2844759T3/en unknown
- 2012-12-12 KR KR1020147019123A patent/KR102027400B1/en active Active
- 2012-12-12 RU RU2014127435A patent/RU2630620C2/en active
- 2012-12-12 MX MX2014007183A patent/MX368484B/en active IP Right Grant
- 2012-12-12 WO PCT/DE2012/001205 patent/WO2013107436A1/en not_active Ceased
- 2012-12-12 JP JP2014546315A patent/JP6313215B2/en active Active
- 2012-12-12 CN CN201280062015.XA patent/CN104428417B/en active Active
- 2012-12-12 DK DK12823073.7T patent/DK2844759T3/en active
- 2012-12-12 US US14/364,238 patent/US11065312B2/en active Active
- 2012-12-12 DE DE112012005213.7T patent/DE112012005213A5/en not_active Withdrawn
-
2014
- 2014-07-10 ZA ZA2014/05034A patent/ZA201405034B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014014390A2 (en) | 2020-12-08 |
| CN104428417B (en) | 2020-05-05 |
| MX2014007183A (en) | 2014-11-25 |
| KR20140105821A (en) | 2014-09-02 |
| RU2014127435A (en) | 2016-02-10 |
| JP2015507472A (en) | 2015-03-12 |
| WO2013107436A8 (en) | 2015-01-15 |
| DE102011121069A1 (en) | 2013-06-13 |
| ES2690792T3 (en) | 2018-11-22 |
| EP2844759A1 (en) | 2015-03-11 |
| CA2859231C (en) | 2019-04-30 |
| US11065312B2 (en) | 2021-07-20 |
| CA2859231A1 (en) | 2013-07-25 |
| KR102027400B1 (en) | 2019-10-04 |
| DE112012005213A5 (en) | 2014-11-13 |
| MX368484B (en) | 2019-10-04 |
| WO2013107436A1 (en) | 2013-07-25 |
| RU2630620C2 (en) | 2017-09-11 |
| BR112014014390B1 (en) | 2022-08-09 |
| ZA201405034B (en) | 2015-12-23 |
| EP2844759B1 (en) | 2018-07-18 |
| CN104428417A (en) | 2015-03-18 |
| DK2844759T3 (en) | 2018-11-05 |
| JP6313215B2 (en) | 2018-04-18 |
| US20150190486A1 (en) | 2015-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2680885B8 (en) | Combination vaccines with lower doses of antigen and/or adjuvant | |
| IL227796A0 (en) | Methods for enhancing immunogen specific immune respones by vectored vaccines | |
| SG11201400432VA (en) | Polypeptide vaccine | |
| ZA201301013B (en) | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells | |
| SG11201401100UA (en) | Antigen-binding molecule inducing immune response to target antigen | |
| IL236650A0 (en) | Mycobacterial antigen vaccine | |
| EP2678005A4 (en) | Muc1 based glycolipopeptide vaccine with adjuvant | |
| ZA201404516B (en) | Vaccines against hpv | |
| AP2013006876A0 (en) | Method of stroing a vaccine containing an aluminium adjuvant | |
| PH12013502174A1 (en) | Vaccine delivery method | |
| IL231043A (en) | Vaccine | |
| ZA201405034B (en) | Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens | |
| IL232173A0 (en) | Antigen presenting cancer vaccine with gamma interferon | |
| WO2013033496A3 (en) | Laser adjuvants for enhancing immune response | |
| GB201119999D0 (en) | Vaccine | |
| ZA201403950B (en) | Vaccine for falciparum malaria | |
| ZA201402071B (en) | Vaccine therapy | |
| FR2998579B1 (en) | METHOD FOR OBTAINING ANTIGEN-SPECIFIC HUMAN ANTIBODIES BY IN VITRO IMMUNIZATION | |
| ZA201503036B (en) | Chimeric vaccine antigens against hepatitis c virus | |
| EP2929894A4 (en) | Vaccination adjuvant, and preparation and vaccines containing same | |
| GB201120109D0 (en) | Malaria vaccine | |
| GB201120000D0 (en) | Vaccine | |
| AU2011901988A0 (en) | Recombinant viral vaccines | |
| GB201109294D0 (en) | Novel vaccine | |
| AP2014007732A0 (en) | Vaccine for falciparum malaria |